The base case analysis found that an integrated home dialysis model compared to current patient pathways is likely not cost-effective. These results were primarily driven by the high baseline costs of dialysis during life-years gained by HHD patients. When excluding baseline dialysis-related treatment costs, the integrated home dialysis model was dominant. New strategies in kidney care patient pathway management should be explored as, under the assumption that dialysis should be funded, the results provide cost-effectiveness evidence for an integrated home dialysis model.